MedKoo Cat#: 558389 | Name: Safrazine Hydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Safrazine Hydrochloride is an irreversible monoamine oxydase inhibitor (MOI).

Chemical Structure

Safrazine Hydrochloride
Safrazine Hydrochloride
CAS#7296-30-2

Theoretical Analysis

MedKoo Cat#: 558389

Name: Safrazine Hydrochloride

CAS#: 7296-30-2

Chemical Formula: C11H17ClN2O2

Exact Mass: 244.1000

Molecular Weight: 244.72

Elemental Analysis: C, 53.99; H, 7.00; Cl, 14.49; N, 11.45; O, 13.08

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Safrazine Hydrochloride;
IUPAC/Chemical Name
[3-(1,3-benzodioxol-5-yl)-1-methyl-propyl]hydrazine Hydrochloride
InChi Key
UOZNXVYMTZITGP-UHFFFAOYSA-N
InChi Code
InChI=1S/C11H16N2O2.ClH/c1-8(13-12)2-3-9-4-5-10-11(6-9)15-7-14-10;/h4-6,8,13H,2-3,7,12H2,1H3;1H
SMILES Code
NNC(C)CCC1=CC=C(OCO2)C2=C1.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 244.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ogata K, Nakayama T, Kawai M. [Treatment of nocturnal periodic hypoxemia with safrazine hydrochloride in a patient with Duchenne muscular dystrophy under nasal intermittent positive pressure ventilation]. Rinsho Shinkeigaku. 1998 Aug;38(8):776-8. Japanese. PubMed PMID: 9916528. 2: Yokoyama T, Karube T, Iwata N. Comparative studies of the effects of RS-8359 and safrazine on monoamine oxidase in-vitro and in-vivo in mouse brain. J Pharm Pharmacol. 1989 Jan;41(1):32-6. PubMed PMID: 2565961. 3: Orikasa S, Sakurada S, Kisara K. Head-twitch response induced by tyramine. Psychopharmacology (Berl). 1980 Jan;67(1):53-9. PubMed PMID: 6245422. 4: Semba J, Nankai M, Maruyama Y, Kaneno S, Watanabe A, Takahashi R. Increase in urinary beta-phenylethylamine preceding the switch from mania to depression: a "rapid cycler". J Nerv Ment Dis. 1988 Feb;176(2):116-9. PubMed PMID: 3339341. 5: Eto S, Noda H, Minemoto M, Noda A. Effect of safrazine, a monoamine oxidase inhibitor bearing a hydrazine-terminal, on phenytoin metabolism in isolated rat hepatocytes. Chem Pharm Bull (Tokyo). 1988 Jan;36(1):456-8. PubMed PMID: 3378307. 6: Orikasa S, Kisara K. [Effects of parasympathetic drugs on head-twitch response induced by tyramine (author's transl)]. Nihon Yakurigaku Zasshi. 1981 May;77(5):477-82. Japanese. PubMed PMID: 7197657. 7: Hamada H, Saito T, Torii J. [A case of optico-neuropathy due to the treatment with monoamine oxidase inhibitor (safrazine) (author's transl)]. Rinsho Shinkeigaku. 1979 Jun;19(6):379-87. Japanese. PubMed PMID: 477139. 8: Orikasa S, Kisara K. A possible mechanism of the tyramine-induced head-twitch response. Eur J Pharmacol. 1982 May 21;80(2-3):163-9. PubMed PMID: 6213417. 9: Inui M, Azuma H, Nishimura T. The effect of monoamine oxidase inhibitor and amine precursors on epileptic seizures. Med J Osaka Univ. 1980 Mar;30(3-4):79-85. PubMed PMID: 6774223. 10: Mato M, Ookawara S, Aikawa E, Kawasaki K. Studies on fluorescent granular perithelium (F.G.P.) of rat cerebral cortex - especially referring to morphological changes in aging. Anat Anz. 1981;149(5):486-501. PubMed PMID: 6974517. 11: KANEKO Z, TANIMUKAI H, NISHINUMA K, NISHIMURA T. Beta-piperonylisopropylhydrazine, a new monoamine oxidase inhibitor as an antidepressant. Psychosomatics. 1963 Mar-Apr;4:99-103. PubMed PMID: 13962210. 12: Hiramatsu M. Brain monoamine levels and E1 mouse convulsions. Folia Psychiatr Neurol Jpn. 1981;35(3):261-6. PubMed PMID: 6173293. 13: Fukushima N. [Role of brain biogenic amines in the central thermoregulatory mechanism of the rat (author's transl)]. Hokkaido Igaku Zasshi. 1975 Jul;50(4):369-85. Japanese. PubMed PMID: 1240080. 14: Inoue T, Izumi T, Honma H, Ohmori T, Denda K, Kasahara T, Koyama T. [Survey and treatment strategy of antidepressant-resistant depression]. Seishin Shinkeigaku Zasshi. 1996;98(5):329-42. Japanese. PubMed PMID: 8741286.